A

Text search

Sort by Default

Display 15 Products per page

Company Analysis: AbbVie
Read More
PharmaVitae explores AbbVie’s prescription pharmaceutical performance and outlook over 2019–29.
January 25, 2021
Find out more
adagloxad simolenin
Read More
Adagloxad simolenin (OBI Pharma) is a carbohydrate-based vaccine comprised of Globo-H conjugated to keyhole limpet hemocyanin. Upon exposure to the synthetic Globo-H vaccine and an immunological adjuvant, the immune system mounts IgM and IgG responses against Globo-H hexasaccharide.
February 26, 2020
Find out more
Avastin
Read More
Avastin (bevacizumab; Roche/Chugai) is a humanized immunoglobulin G1 monoclonal antibody directed against vascular endothelial growth factor (VEGF).
February 26, 2020
Find out more
Abraxane
Read More
Abraxane (nab-paclitaxel; Bristol-Myers Squibb) is a novel albumin-bound formulation of paclitaxel. Paclitaxel is an insoluble taxane classified as an anti-microtubule agent; it stops the growth of tumors by inhibiting mitosis during metaphase.
February 26, 2020
Find out more
Aramchol
Read More
Aramchol (arachidyl amido cholanoic acid; Galmed) is a conjugate of cholic acid and arachidic acid, and belongs to the synthetic fatty acid bile acid conjugates (FABACs) family. Aramchol inhibits the liver enzyme stearoyl-CoA desaturase 1 inhibitor (SCD1), and as a result fatty acid synthesis is reduced while fatty acid oxidation is increased. Additionally, Aramchol has hypocholesterolemic effects due to the upregulation of ATP-binding cassette transporter 1 (ABCA1). Ultimately, Aramchol causes incomplete SCD inhibition while also being anti-atherogenic.
July 22, 2019
Find out more
Atripla
Read More
Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Bristol-Myers Squibb) is a single-tablet regimen approved for the treatment of HIV-1 infection.
June 28, 2019
Find out more
ALKS 5461
Read More
ALKS 5461 (Alkermes) is a fixed-dose combination of buprenorphine, a mu opioid receptor partial agonist and kappa opioid receptor antagonist, and samidorphan (ALKS 33), which is a proprietary opioid modulator.
March 29, 2019
Find out more
Abilify/Abilify Maintena
Read More
Abilify (aripiprazole; Otsuka/Lundbeck) is an atypical antipsychotic that contains aripiprazole, a partial agonist of dopamine receptor D2 and serotonin receptor 5-HT1A, and antagonist of the 5-HT2A receptor.
March 29, 2019
Find out more
Afinitor
Read More
Afinitor (everolimus; Novartis) is an orally available analog of the mammalian target of rapamycin (mTOR), which mediates the signal transduction pathways required for cell cycle progression from G1 to S phase.
March 6, 2019
Find out more
abexinostat
Read More
Abexinostat (Xynomic Pharmaceuticals) is a broad histone deacetylase (HDAC) inhibitor. HDAC enzymes (also known as lysine deacetylase) cleave acetyl groups from N-acetyl lysine amino acids on a histone.
March 6, 2019
Find out more
Arzerra
Read More
Arzerra (ofatumumab; Genmab/Novartis) is a fully human immunoglobulin G1 and high-affinity antibody that targets a novel epitope on cluster of differentiation 20 (CD20) on the B-cell membrane.
January 31, 2019
Find out more
Aliqopa
Read More
Aliqopa (copanlisib; Bayer) is a small molecule phosphoinositide 3-kinase (PI3K) inhibitor with high selectivity for the p110-alpha/delta catalytic subunits. The PI3K pathway is crucial for normal B-cell development, and is subverted by follicular lymphoma (FL) to promote survival and growth.
January 31, 2019
Find out more
Aurora-GT
Read More
United Therapeutics is developing a gene therapy product called Aurora-GT (endothelial nitric oxide-synthase-enhanced endothelial progenitor cells)
October 29, 2018
Find out more
Adempas
Read More
Adempas (riociguat; Bayer/Merck & Co) is a first-in-class drug that activates soluble guanylyl cyclase (sGC), a key enzyme in nitric oxide-mediated vasodilation of vascular smooth muscle cells.
October 29, 2018
Find out more
Adcirca
Read More
Launching after Revatio, Adcirca became the second-to-market PDE5 inhibitor upon its approval in major markets in 2009. Inhibiting the PDE5 enzyme enhances the effect of the endogenous vasodilator, nitric oxide (NO).
October 29, 2018
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *